1 – 28 of 28
- show: 250
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2022
-
Mark
Idelalisib in relapsed/refractory diffuse large B-cell lymphoma : results from a Nordic Lymphoma Group phase II trial
(
- Contribution to journal › Letter
-
Mark
Molecular features encoded in the ctDNA reveal heterogeneity and predict outcome in high-risk aggressive B-cell lymphoma
(
- Contribution to journal › Article
- 2020
-
Mark
SN 2019ehk: A Double-Peaked Ca-rich Transient with Luminous X-ray Emission and Shock-Ionized Spectral Features
(
- Contribution to journal › Article
- 2019
-
Mark
Large expert-curated database for benchmarking document similarity detection in biomedical literature search
(
- Contribution to journal › Article
-
Mark
Monitoring CAR-T-Cell Therapies Using the Nordic Healthcare Databases
(
- Contribution to journal › Article
-
Mark
Relapse Risk and Loss of Lifetime After Modern Combined Modality Treatment of Young Patients With Hodgkin Lymphoma : A Nordic Lymphoma Epidemiology Group Study
(
- Contribution to journal › Article
-
Mark
Discovery of a chemical probe for PRDM9
(
- Contribution to journal › Article
- 2018
-
Mark
Simplicity at the cost of predictive accuracy in diffuse large B-cell lymphoma : A critical assessment of the R-IPI, IPI, and NCCN-IPI
(
- Contribution to journal › Article
- 2017
-
Mark
Frequency and clinical implications of SOX11 expression in Burkitt lymphoma
(
- Contribution to journal › Letter
-
Mark
Outcome of peripheral T-cell lymphoma in first complete remission : a Danish-Swedish population-based study
(
- Contribution to journal › Article
-
Mark
TP53 mutations identify younger mantle cell lymphoma patients who do not benefit from intensive chemoimmunotherapy
(
- Contribution to journal › Article
-
Mark
Molecular Monitoring after Autologous Stem Cell Transplantation and Preemptive Rituximab Treatment of Molecular Relapse; Results from the Nordic Mantle Cell Lymphoma Studies (MCL2 and MCL3) with Median Follow-Up of 8.5 Years
(
- Contribution to journal › Article
- 2016
-
Mark
No survival benefit associated with routine surveillance imaging for Hodgkin lymphoma in first remission: a Danish-Swedish population-based observational study.
2016) In British Journal of Haematology(
- Contribution to journal › Article
-
Mark
15-year follow-up of the Second Nordic Mantle Cell Lymphoma trial (MCL2) : Prolonged remissions without survival plateau
(
- Contribution to journal › Article
- 2015
-
Mark
Routine Imaging for Diffuse Large B-Cell Lymphoma in First Complete Remission Does Not Improve Post-Treatment Survival: A Danish-Swedish Population-Based Study.
(
- Contribution to journal › Article
-
Mark
miR-18b overexpression identifies mantle cell lymphoma patients with poor outcome and improves the MIPI-B prognosticator.
(
- Contribution to journal › Article
-
Mark
F-18-fluorodeoxyglucose-positron emission tomography/computed tomography after one cycle of chemotherapy in patients with diffuse large B-cell lymphoma: results of a Nordic/US intergroup study
(
- Contribution to journal › Article
- 2014
-
Mark
Real world data on primary treatment for mantle cell lymphoma: a Nordic Lymphoma Group observational study.
(
- Contribution to journal › Article
-
Mark
Nordic MCL3 study: Y-90-ibritumomab-tiuxetan added to BEAM/C in non-CR patients before transplant in mantle cell lymphoma
(
- Contribution to journal › Article
-
Mark
Fall, recovery, and characterization of the Novato L6 chondrite breccia
(
- Contribution to journal › Article
- 2012
-
Mark
Upfront Autologuos Stem-Cell Transplantation in Peripheral T-Cell Lymphoma: NLG-T-01.
(
- Contribution to journal › Article
-
Mark
Nordic MCL2 trial update: six-year follow-up after intensive immunochemotherapy for untreated mantle cell lymphoma followed by BEAM or BEAC plus autologous stem-cell support: still very long survival but late relapses do occur
(
- Contribution to journal › Article
- 2011
-
Mark
T Cells in Tumors and Blood Predict Outcome in Follicular Lymphoma Treated with Rituximab
(
- Contribution to journal › Article
- 2010
-
Mark
The Mantle Cell Lymphoma International Prognostic Index (MIPI) is superior to the International Prognostic Index (IPI) in predicting survival following intensive first-line immunochemotherapy and autologous stem cell transplantation (ASCT)
(
- Contribution to journal › Article
-
Mark
Favorable Outcome In ALK Negative Anaplastic Large Cell Lymphoma Following Intensive Induction Chemotherapy and Autologous Stem Cell Transplantation (ASCT) a Prospective Study by the Nordic Lymphoma Group (NLG T 01)
(
- Contribution to journal › Published meeting abstract
-
Mark
Intensive Induction Chemotherapy Followed by Autologous Stem Cell Transplantation (ASCT) In Patients with Enteropathy Associated T Cell Lymphoma a Prospective Study by the Nordic Lymphoma Group (NLG T 01)
(
- Contribution to journal › Published meeting abstract
- 2008
-
Mark
Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo-purged stem cell rescue: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group
(
- Contribution to journal › Article
- 2005
-
Mark
Radioimmunoterapi ved non-Hodgkins lymfom
(
- Contribution to journal › Article